Logo

To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the cookie policy

Get updates

When you see uveal melanoma, you can't afford to wait

Watch brief video

Though it may start as an isolated tumor of the eye, uveal melanoma (UM) metastasizes in up to 50% of patients,
becoming a systemic disease.1

As metastatic UM (mUM) runs its course, treatment options are limited and patients face a median survival of up to 12 months.2 So, when you see mUM, think fast.

About uveal 
melanoma

Presentation and 
symptoms, risk factors 
and management

Uveal melanoma vs
cutaneous melanoma

Intrinsic differences 
between UM and 
cutaneous melanoma (CM)

Advanced uveal 
melanoma

Guideline-based 
recommendations 
for mUM

Resources

Clinical perspectives and 
resources for patients 
and caregivers

    References:
  1. Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38-44. doi:10.1136/b‌jophth‌almol-201‌6-30‌90‌4
  2. Nathan P, Cohen V, Coupland S, et al. Uveal melanoma UK national guidelines. Eur J Cancer. 2015;51(16):2‌404-2‌41‌2. doi:10.1016/j.ejca.2015.07.013
Think uveal melanoma brochure

Think uveal melanoma brochure

Please download the brochure for more information on uveal melanoma.

Download